PF-03084014
Sponsors
Pfizer, National Cancer Institute (NCI), Jules Bordet Institute, University of Colorado, Denver
Conditions
Advanced Solid TumorsAggressive FibromatosisBreast CancerBreast Cancer MetastaticDesmoid TumorDesmoid TumorsMetastatic Cancer PancreasNeoplasm
Phase 1
A Trial In Patients With Advanced Cancer And Leukemia
CompletedNCT00878189
Start: 2009-06-25End: 2016-11-22Updated: 2019-11-12
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
TerminatedNCT01876251
Start: 2013-11-04End: 2015-12-24Updated: 2019-03-15
A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors
WithdrawnNCT02462707
Start: 2015-07-31End: 2016-10-31Updated: 2015-10-07
Phase 2
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
CompletedNCT01981551
Start: 2013-10-31End: 2023-12-01Updated: 2024-02-06
Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
TerminatedNCT02109445
Start: 2014-09-03End: 2014-11-06Updated: 2019-01-10
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
TerminatedNCT02299635
Start: 2015-02-03End: 2016-01-14Updated: 2019-01-08
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
WithdrawnNCT02338531
Start: 2015-06-30End: 2018-12-31Updated: 2016-04-29